About Pear Therapeutics
Pear Therapeutics was a Healthcare company based in Boston (United States) founded in 2013 by William Greene, Stephen Kennedy Smith, Ian Mcfarland, and Corey McCann. Pear Therapeutics provides cloud-based digital solutions for managing chronic health conditions effectively. It operates on a B2B model. Pear Therapeutics has raised $266.34 million across 9 funding rounds from investors including Novartis, HHS and Temasek. The company has 207 employees. Pear Therapeutics has completed 1 acquisition, including Firsthand Technology. Pear Therapeutics was last valued at $1.6 billion in June 2021. Its chief executive, as recorded, is Corey McCann. The company is recorded as dissolved. Its focus areas include Digital Health, Therapeutics and Chronic Disease Management. Its competitors include DarioHealth, Welldoc and Spiras Health; 3 of its 3 listed competitors have raised funding.
Company details
Pear Therapeutics operates with a B2B model, focusing on providing healthcare solutions, providing digital health services, therapeutics, and chronic disease management. Pear Therapeutics provides cloud-based digital solutions for managing chronic health conditions effectively. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
- Headquarters Boston, United States
- Employees 207
- Founders William Greene, Stephen Kennedy Smith, Ian Mcfarland, Corey McCann
- Stage Unicorn
- SectorsHealthcare
- Website peartherapeutics.com
- Social LinkedIn X
- Annual Revenue$12.7 M (USD)as on Dec 31, 2022
- Net Profit-$75.49 M (USD)as on Dec 31, 2022
- EBITDA-$123.35 M (USD)as on Dec 31, 2022
- Total Equity Funding$266.34M (USD)
in 9 rounds
- InvestorsNovartis
& 17 more
- Employee Count207
- Investments & Acquisitions
Funding Insights of Pear Therapeutics
Pear Therapeutics has successfully raised a total of $266.34M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $266.34M
- Total Rounds 9
- Investors Count 18
All 9 funding rounds of Pear Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | Post-IPO | – | – | – | |
| Dec 2020 | $132M | Series D | – | SoftBank Vision Fund | |
| Jul 2020 | Debt – Conventional | – | – | ||
| Sep 2019 | $214,833 | Grant | – | – | |
| Jan 2019 | $64.34M | Series C | – | Temasek | |
| Jan 2018 | $50M | Series B | – | Temasek | |
| Jul 2017 | $1.18M | Grant | – | – | |
| Feb 2016 | $20M | Series A | – | 5AM Ventures, Arboretum Ventures | |
| Mar 2015 | Seed | – | 5AM Ventures | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Pear Therapeutics
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.6B (Jun 2021). 18 investors in total: 18 institutional.
Investors in Pear Therapeutics
Pear Therapeutics has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, HHS and Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Healthcare venture capital investments are made by Arboretum Ventures. | arboretumvc.com | Ann Arbor, United States | ||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Tech & Life Science focused VC firm investing in the US | jazzvp.com | San Francisco, United States | ||
Government-backed investments are directed toward healthcare, fintech, and various sectors. | edbi.com | Singapore, Singapore | ||
| pilothouseventures.com | ||||
VC firm investing primarily in China, the US and Israel | shanda.com | Menlo Park, United States | ||
BB Collaborative is focused on funding mindfulness and mind-training solutions. | 2012 | bbcollaborative.com | ||
early & growth stage tech and life sciences focused VC firm investing primarily in China and the US | trustbridgepartners.com | Shanghai, China |
Investor details for Pear Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pear Therapeutics
20 people are tracked at Pear Therapeutics (8 in leadership, 6 in board & advisors, 6 in team); the tracked headcount is 207.
| Name | Role | Group |
|---|---|---|
William Greene | Co-Founder | Leadership |
Stephen Kennedy Smith | Co-Founder | Leadership |
Ian Mcfarland | Co-Founder | Leadership |
Corey McCann | Co-Founder, CEO | Leadership |
Chris Guiffre | CFO & COO | Leadership |
Brian Prunier | VP, Patient Services | Leadership |
Anthony Watson | VP, Regulatory Affairs | Leadership |
Robert D. | Sr. Director, Information Security And Infrastructure | Leadership |
Nancy M. Schlichting | Board Member | Board & advisors |
Kirthiga Reddy | Board Member | Board & advisors |
Tim Wicks | Board Member | Board & advisors |
Alison Bauerlein | Board Member | Board & advisors |
Shiva Rajaraman | Board Member | Board & advisors |
Paul Mango | Board Member | Board & advisors |
Jia Yue Mo | Software Engineer | Team |
Caitlin Cotter | Staff Software Engineer | Team |
Brittany Cyrus | Enrollment & Adherence Specialist | Team |
Judith Deguzman | Quality Systems Specialist | Team |
Kanwar B. | Software Quality Assurance Manager | Team |
Simon Rubinsky | Account Manager | Team |
Complete people profiles for Pear Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pear Therapeutics
Pear Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Firsthand Technology.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Virtual Reality Games, Simulations & Therapy | firsthand.com | San Francisco, United States | 1995 | Jan 2020 | •••• |
Complete acquisition details for Pear Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Pear Therapeutics
6 dated milestones of Pear Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Pear Therapeutics is founded.
- Funding First funding round.
- Acquisition Acquires Firsthand Technology.
- Milestone Reaches Unicorn status.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Pear Therapeutics
Pear Therapeutics has 3 listed competitors in our database, 3 of them funded. They include DarioHealth, Welldoc and Spiras Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dariohealth.com | 2011 | New York, United States | $6.01M | 196 | Chronic conditions are managed via a personalized digital platform. | |
| welldoc.com | 2005 | Columbia, United States | $72.08M | 65 | Mobile health products for chronic disease management are offered. | |
| spirashealth.com | 2015 | Nashville, United States | $14.15M | 37 | Asthma and COPD symptoms are managed through clinical services. |
Detailed competitors of Pear Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Pear Therapeutics (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pear Therapeutics
Complete news archive for Pear Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pear Therapeutics
Pear Therapeutics was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Pear Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Corey McCann is the CEO of Pear Therapeutics, as recorded in our data. They have also founded this company.
Pear Therapeutics is a funded company, having raised a total of $266.34M across 9 funding rounds to date.
Pear Therapeutics has 207 employees.
Annual revenue of Pear Therapeutics is $12.7M as on Dec 31, 2022.
Pear Therapeutics operates with a B2B model, focusing on providing healthcare solutions, providing digital health services, therapeutics, and chronic disease management. Pear Therapeutics provides cloud-based digital solutions for managing chronic health conditions effectively. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Pear Therapeutics's top competitors include Welldoc, DarioHealth and Spiras Health.
Pear Therapeutics has made 1 acquisition, including Firsthand Technology.
Pear Therapeutics has 18 investors. Key investors include Novartis, HHS, Temasek, SoftBank Vision Fund, and Perceptive Advisors.
The valuation of Pear Therapeutics is $1.6B as of Jun 2021.